Market News AIOpen the app

ORIC Pharmaceuticals shares new research on rinzimetostat at the ESMO Congress 2026.

TrialRead the original at globenewswire.com
Good for ORIC

ORIC reported early findings suggesting rinzimetostat may limit tumor adaptation and improve sensitivity to another treatment. The results support an ongoing Phase 3 study, but do not show that patients benefit.

ORIC · ORIC Pharmaceuticals

AI read · Good for ORIC

The AI's read

The findings give ORIC a scientific reason to keep testing rinzimetostat. The work is still preclinical and does not show that patients will benefit. Still, the possible advantages and support for a Phase 3 study make this favorable for ORIC.

Get alerts for ORIC

Follow ORIC Pharmaceuticals (ORIC) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for ORIC
Free on the App Store and Google Play, or on the web.